HENGRUI PHARMA (01276.HK): SHR-1179 injection approved for clinical trial, targeting weight management indication

NewTimeSpace News: On 7 September 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) announced that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. had received a Clinical Trial Approval Notice from the National Medical Products Administration (NMPA) for SHR-1179 injection, with clinical trials to commence shortly.

The announcement showed that the clinical trial application for SHR-1179 injection was accepted on 1 June 2026 (acceptance no. CXSL2600586) and, upon review, was found to comply with the relevant requirements for drug registration, with clinical trials for the weight management indication approved. SHR-1179 injection is a therapeutic Class 1 biological product independently developed by the company, intended for the weight management indication, with no drug targeting the same pathway yet approved in China or overseas. As of the date of the announcement, cumulative R&D investment in the SHR-1179 project amounted to approximately RMB 24.2 million (unaudited).

The company reminded that after obtaining the clinical trial approval, the drug still needs to undergo clinical trials and NMPA evaluation and approval before it can be manufactured and marketed, and its R&D and launch are subject to uncertainties.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.